Further assessment of cytotoxic responses against multiple metastatic prostate cancer cell lines and/or primary prostate cancer cell lines are needed and, ideally, these would be combined with an assessment of “triggering” receptor ligand interactions in order to further interrogate the efficacy of using CTV-1 primed and IL-2 activated NK cell populations for the treatment of prostate cancer. This evidence concerns the gene IL2 and prostate cancer.